5 studies found for:    CARE-MS
Show Display Options
Rank Status Study
1 Completed Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies
Condition: Multiple Sclerosis
Intervention:
2 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab;   Biological: Interferon beta-1a
3 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab 12 mg;   Biological: Alemtuzumab 24 mg;   Biological: Interferon beta-1a
4 Active, not recruiting An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: alemtuzumab
5 Enrolling by invitation Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:

Indicates status has not been verified in more than two years